| A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma (NCT04047251) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2019-11-14 |
| Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments (NCT04058756) | Novartis Pharmaceuticals | 2019-10-30 |
| A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors (NCT03889275) | MedImmune LLC | 2019-10-24 |
| Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug (NCT04095273) | Bayer | 2019-09-30 |
| Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors (NCT04087018) | Arcus Biosciences, Inc. | 2019-09-24 |
| A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors (NCT03934359) | Shanghai De Novo Pharmatech Co., Ltd. | 2019-09-18 |
| A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors (NCT06239155) | Ascentawits Pharmaceuticals, Ltd | 2019-09-03 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors (NCT04049617) | Gilead Sciences | 2019-08-26 |
| A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer (NCT04069026) | Bayer | 2019-08-15 |
| Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors (NCT03945253) | Astellas Pharma Inc | 2019-08-05 |
| To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation (NCT04052971) | Abion Inc | 2019-08-01 |
| Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (NCT03968653) | Debiopharm International SA | 2019-07-30 |
| First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation (NCT04006301) | Janssen Research & Development, LLC | 2019-07-26 |
| A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors (NCT03910530) | Incyte Biosciences Japan GK | 2019-07-22 |
| Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors (NCT03901950) | Evopoint Biosciences Inc. | 2019-07-01 |
| Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors (NCT03895684) | Salarius Pharmaceuticals, LLC | 2019-06-25 |
| Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors (NCT03897283) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-06-20 |
| Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors (NCT03954704) | Gilead Sciences | 2019-06-03 |
| A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors (NCT05649761) | Qilu Pharmaceutical Co., Ltd. | 2019-05-29 |
| Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer (NCT03991494) | BeiGene | 2019-05-29 |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (NCT03893955) | AbbVie | 2019-05-21 |
| A Study of OKI-179 in Patients With Solid Tumors (NCT03931681) | OnKure, Inc. | 2019-05-08 |
| A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (NCT03752398) | Xencor, Inc. | 2019-05-01 |
| Study of TP-3654 in Patients With Advanced Solid Tumors (NCT03715504) | Sumitomo Pharma America, Inc. | 2019-04-16 |
| First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors (NCT03869632) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2019-03-19 |
| A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (NCT03854227) | Pfizer | 2019-03-14 |
| Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NCT03461952) | Canadian Cancer Trials Group | 2019-03-11 |
| AMG 404 in Patients With Advanced Solid Tumors (NCT03853109) | Amgen | 2019-03-05 |
| A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) (NCT03861793) | Mural Oncology, Inc | 2019-02-26 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (NCT03841110) | Fate Therapeutics | 2019-02-15 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (NCT03797326) | Merck Sharp & Dohme LLC | 2019-02-12 |
| A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma (NCT03852251) | Akeso | 2019-01-18 |
| A Study of ASP1951 in Subjects With Advanced Solid Tumors (NCT03799003) | Astellas Pharma Global Development, Inc. | 2019-01-14 |
| Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer (NCT03654547) | TransThera Sciences (Nanjing), Inc. | 2019-01-08 |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors (NCT03604783) | Sumitomo Pharma America, Inc. | 2018-12-26 |
| Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) (NCT03739138) | Merck Sharp & Dohme LLC | 2018-12-18 |
| KN046 in Subjects With Advanced Solid Tumors and Lymphoma (NCT03733951) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2018-12-18 |
| A Study of CS1001 in Subjects with Advanced Solid Tumors (NCT03744403) | CStone Pharmaceuticals | 2018-12-04 |
| TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors (NCT03387917) | Swiss Cancer Institute | 2018-11-12 |
| A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors (NCT03666143) | BeiGene | 2018-11-01 |
| FPT155 in Patients With Advanced Solid Tumors (NCT04074759) | Five Prime Therapeutics, Inc. | 2018-10-18 |
| Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors (NCT03692520) | Sinocelltech Ltd. | 2018-09-30 |
| A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. (NCT03545971) | Innovent Biologics (Suzhou) Co. Ltd. | 2018-09-25 |
| Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers (NCT03641794) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2018-09-07 |
| IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (NCT03665129) | Innate Pharma | 2018-09-07 |
| A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies (NCT03522142) | Incyte Corporation | 2018-08-27 |
| The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. (NCT03577704) | Shanghai Henlius Biotech | 2018-08-08 |
| A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (NCT03588650) | Shanghai Henlius Biotech | 2018-08-07 |
| Study to Evaluate CCS1477 in Advanced Tumours (NCT03568656) | CellCentric Ltd. | 2018-07-23 |
| A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors (NCT03595059) | AbbVie | 2018-07-13 |
| First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors (NCT03429218) | Sumitomo Pharma America, Inc. | 2018-07-10 |
| Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33 (NCT03544905) | Haihe Biopharma Co., Ltd. | 2018-07-05 |
| A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors (NCT03565445) | Astellas Pharma Global Development, Inc. | 2018-07-02 |
| Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors (NCT03010982) | Epizyme, Inc. | 2018-06-20 |
| Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors (NCT03490669) | AstraZeneca | 2018-05-21 |
| Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors (NCT03529526) | Alphamab (Australia) Co Pty Ltd. | 2018-05-21 |
| A Study of MRG003 in Patients With Advanced Solid Tumors (NCT04868344) | Shanghai Miracogen Inc. | 2018-05-09 |
| A Phase I Study of MSB2311 in Advanced Solid Tumors (NCT03463473) | Suzhou Transcenta Therapeutics Co., Ltd. | 2018-04-12 |
| A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors (NCT03497429) | Takeda | 2018-04-05 |
| Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors (NCT03472352) | Hangzhou Converd Co., Ltd. | 2018-04-01 |
| FPA150 in Patients With Advanced Solid Tumors (NCT03514121) | Five Prime Therapeutics, Inc. | 2018-03-27 |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (NCT03297606) | Canadian Cancer Trials Group | 2018-03-23 |
| A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer (NCT03440450) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2018-03-22 |
| An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma (NCT03439761) | SciClone Pharmaceuticals | 2018-03-07 |
| Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors (NCT03415659) | Hubei Biological Medicine Industrial Technology Institute Co., Ltd. | 2018-03-05 |
| Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma (NCT03361358) | Agios Pharmaceuticals, Inc. | 2018-03-01 |
| MGD009/MGA012 Combination in Relapsed/Refractory Cancer (NCT03406949) | MacroGenics | 2018-02-27 |
| IMX-110 in Patients With Advanced Solid Tumors (NCT03382340) | Immix Biopharma Australia Pty Ltd | 2018-02-15 |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (NCT03319459) | Fate Therapeutics | 2018-01-18 |
| UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma (NCT03322384) | University of California, Davis | 2018-01-17 |
| Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors (NCT03348514) | CicloMed LLC | 2018-01-15 |
| Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors (NCT03864042) | Pfizer | 2018-01-02 |
| ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors (NCT06556108) | Xinqiao Hospital of Chongqing | 2018-01-01 |
| ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors (NCT03525795) | Constellation Pharmaceuticals | 2017-12-14 |
| A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers (NCT03251378) | Hutchison Medipharma Limited | 2017-12-11 |
| A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors (NCT04335604) | Onconic Therapeutics Inc. | 2017-12-06 |
| Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN) (NCT03320525) | Herlev Hospital | 2017-11-29 |
| Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors (NCT03379259) | BeiGene | 2017-11-27 |
| CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors (NCT03113188) | CanBas Co. Ltd. | 2017-10-25 |
| AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations (NCT03310541) | Memorial Sloan Kettering Cancer Center | 2017-10-11 |
| This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001 (NCT03292783) | ABL Bio, Inc. | 2017-09-18 |
| A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT03260322) | Astellas Pharma Global Development, Inc. | 2017-09-08 |
| A Trial of HTI-1090 in Subjects With Advanced Solid Tumors (NCT03208959) | Atridia Pty Ltd. | 2017-08-30 |
| Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors (NCT03317743) | Idience Co., Ltd. | 2017-08-29 |
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms (NCT03219268) | MacroGenics | 2017-08-18 |
| A Phase I Study of AL8326 in Advanced Solid Tumor (NCT04890587) | Advenchen Laboratories Nanjing Ltd. | 2017-08-17 |
| M8891 First in Human in Solid Tumors (NCT03138538) | EMD Serono Research & Development Institute, Inc. | 2017-08-08 |
| A Study of TAS-116 in Patients With Solid Tumors (NCT02965885) | Taiho Oncology, Inc. | 2017-07-10 |
| Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) (NCT03179436) | Merck Sharp & Dohme LLC | 2017-07-02 |
| Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors (NCT03713905) | Guangzhou Gloria Biosciences Co., Ltd. | 2017-07-01 |
| Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients (NCT03256331) | Belx Bio-Pharmaceutical (Taiwan) Corporation | 2017-06-21 |
| A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients (NCT03133247) | Atridia Pty Ltd. | 2017-06-01 |
| A Study of SY-1365 in Adult Patients With Advanced Solid Tumors (NCT03134638) | Syros Pharmaceuticals | 2017-05-12 |
| Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) (NCT03065023) | Merck Sharp & Dohme LLC | 2017-04-25 |
| A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (NCT03082209) | AbbVie | 2017-03-20 |
| A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors (NCT03034304) | HRYZ Biotech Co. | 2017-02-22 |
| An Open-Label Pharmacokinetics and Safety Study of Talazoparib (NCT02997163) | Pfizer | 2017-02-21 |
| A First-in-Human Study of PRL3-ZUMAB (NCT03191682) | National University Hospital, Singapore | 2017-02-20 |
| A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) (NCT02994953) | EMD Serono Research & Development Institute, Inc. | 2017-01-31 |
| Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody (NCT04068519) | BeiGene | 2016-12-28 |